Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure

This is an interventional basic science trial for Primary Parathyroid Adenomas focused on measuring Primary hyperparathyroidism, High Intensity Focused Ultrasound, Parathyroid tumor, Parathyroid hormone, Calcium Read More

Inclusion Criteria:

• Male or female patient 18 years or older.
• Patients with diagnosed primary hyperparathyroidism (clinical symptoms and/or biochemical disturbances) scheduled for parathyroidectomy.
• One diseased parathyroid gland, visualized by ultrasonography.
• The diseased targeted parathyroid gland accessible for HIFU treatment (anonymised ultrasonographic images to be sent to the sponsor's technical team for validation).
• Normal pretreatment nasofibroscopy.
• Voluntary signed informed consent.

Exclusion Criteria:

• Inaccessibility or high risk of targeting neighbouring structures, as evidenced by:

  • Targeted area located less than 2 mm laterally from the oesophagus or the carotid artery
  • Targeted area located less than 3 mm laterally from the trachea,
  • Significant hyperechoic area with a posterior shadow located less than 10 mm behind the targeted area (behind to be understood as posterior to the targeted area in the direction of the HIFU beam)
• Investigator appreciation of any abnormal blood test that could contraindicate treatment with HIFU (bleeding abnormalities)
• Known spondylitis of the neck vertebrae
• Head and/or neck disease that prevents hyperextension of neck.
• Known history of parathyroid or other neoplasias in the neck region.
• History of neck irradiation
• Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit
• Pregnant or lactating woman.
• Female patient of childbearing age if not having a suitable contraception method.
• Patients who have received any investigational drug or device within the last 15 days and/or patients who are currently participating in another clinical trial.